PHAR Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

13.082

Open

13.070

VWAP

12.30

Vol

96.10K

Mkt Cap

1.16B

Low

11.830

Amount

1.18M

EV/EBITDA(TTM)

21.15

Total Shares

70.63M

EV

1.09B

EV/OCF(TTM)

22.44

P/S(TTM)

2.79

Pharming Group NV is a biopharmaceutical company based in the Netherlands. The Company is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The Company's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.

Show More

Events Timeline

(ET)

2026-05-07

06:00:00

Pharming Sees FY26 Operating Expenses at $330M-$335M

2026-05-07

06:00:00

Company Reports Q1 Revenue of $72.45M, Below Consensus

2026-03-24 (ET)

2026-03-24

11:10:00

Pharming Group's Joenja Approved in Japan for APDS Treatment

2026-02-02 (ET)

2026-02-02

09:00:00

U.S. Stock Futures Weaker, Tech Stocks Under Pressure

2026-02-01 (ET)

2026-02-01

21:30:00

Ford in Talks with Xiaomi for U.S. Market Entry

2026-02-01

18:50:00

Pharming Group Receives Complete Response Letter from FDA for Joenja Application

News

Newsfilter

05-07Newsfilter

PinnedPharming Presents Research Findings at CIS Annual Meeting

seekingalpha

05-07seekingalpha

Pharming Releases 2026 Financial Guidance Amid Revenue Decline

NASDAQ.COM

05-07NASDAQ.COM

Pharming to Present Multiple Studies at 2026 Clinical Immunology Society Annual Meeting

Newsfilter

04-23Newsfilter

Pharming Group to Report Q1 2026 Financial Results on May 7

Globenewswire

04-13Globenewswire

Pharming Group Faces Securities Fraud Investigation

Newsfilter

04-07Newsfilter

Pharming Group to Participate in Investor Conferences

2 Analyst Rating

Wall Street analysts forecast PHAR stock price to rise

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

37.00

Averages

39.50

High

42.00

Current: 0.000

Low

37.00

Averages

39.50

High

42.00

Oppenheimer

Oppenheimer

Outperform

maintain

$41 -> $40

AI Analysis

2026-05-08

New

Reason

Oppenheimer

Oppenheimer

Price Target

$41 -> $40

AI Analysis

2026-05-08

New

maintain

Outperform

Reason

Oppenheimer lowered the firm's price target on Pharming to $40 from $41 and keeps an Outperform rating on the shares. The firm notes the company reported Q1 results with Ruconest revenues taking a larger than anticipated seasonal hit, driving disappointing Q1 top-line revenues of $72.4M vs. estimates. Given the magnitude of the seasonal revenue fall off compared to last year, Oppenheimer sees meeting guidance as a challenge with management reiterating prior full year guidance of $405M-$415M.

Canaccord

Whitney Ijem

initiated

$37

2026-04-10

Reason

Canaccord

Whitney Ijem

Price Target

$37

2026-04-10

initiated

Reason

As previously reported, Canaccord analyst Whitney Ijem initiated coverage of Pharming with a Buy rating and $37 price target. Lead product Ruconest, a complex biologic approved in the U.S. since 2014 for the on-demand treatment of hereditary angioedema attacks, will see its IP expire in 2026 and the HAE competitive landscape is evolving, notes the analyst. However, the firm continues to model growth in the near-to-medium term, given that it doesn't anticipate biosimilar competition given the proprietary, transgenic rabbit-based manufacturing process and Ruconest's high-efficacy product profile, the analyst tells investors.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for PHAR

Unlock Now

Valuation Metrics

The current forward P/E ratio for Pharming Group NV (PHAR.O) is 56.18, compared to its 5-year average forward P/E of -48.60. For a more detailed relative valuation and DCF analysis to assess Pharming Group NV's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-48.60

Current PE

56.18

Overvalued PE

224.29

Undervalued PE

-321.49

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

143.06

Current EV/EBITDA

52.90

Overvalued EV/EBITDA

402.50

Undervalued EV/EBITDA

-116.38

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

5Y Average PS

2.69

Current PS

2.59

Overvalued PS

3.24

Undervalued PS

2.15

Financials

AI Analysis

Annual

Quarterly

Whales Holding PHAR

Trading Trends

People Also Watch

Frequently Asked Questions

What is Pharming Group NV (PHAR) stock price today?

The current price of PHAR is 12 USD — it has decreased -26.83

What is Pharming Group NV (PHAR)'s business?

Pharming Group NV is a biopharmaceutical company based in the Netherlands. The Company is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The Company's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.

What is the price predicton of PHAR Stock?

Wall Street analysts forecast PHAR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PHAR is39.50 USD with a low forecast of 37.00 USD and a high forecast of 42.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Pharming Group NV (PHAR)'s revenue for the last quarter?

Pharming Group NV revenue for the last quarter amounts to NaN USD, decreased

What is Pharming Group NV (PHAR)'s earnings per share (EPS) for the last quarter?

Pharming Group NV. EPS for the last quarter amounts to USD, decreased

How many employees does Pharming Group NV (PHAR). have?

Pharming Group NV (PHAR) has 382 emplpoyees as of May 08 2026.

What is Pharming Group NV (PHAR) market cap?

Today PHAR has the market capitalization of 1.16B USD.